Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global
biotechnology company focused on developing and commercializing
novel medicines for rare diseases, today announced financial
results for the full-year ended December 31, 2023.
“In 2023, Amicus made tremendous progress across
all our strategic priorities,” said Bradley Campbell, President and
Chief Executive Officer of Amicus Therapeutics, Inc. “We
strengthened our leadership position in Fabry and Pompe disease
globally and achieved our goal of non-GAAP profitability in the
fourth quarter. Patient demand for Galafold exceeded our
expectations and grew at the highest rate seen in the last four
years and we continue to be excited by the long-term growth of
this important medicine. We also successfully launched our second
commercial therapy, Pombiliti + Opfolda, in the three largest Pompe
disease markets. In 2024, we will continue to drive significant top
line revenue growth supported by sustained double-digit Galafold
performance and the successful ongoing global commercial launch of
Pombiliti + Opfolda putting us on track for our first full year of
non-GAAP profitability. Amicus is at a major inflection point and
strongly positioned to continue to advance our mission of
delivering groundbreaking new medicines to thousands of people
living with rare diseases and creating value for our
shareholders.”
Corporate Highlights:
- Total
revenues for the full-year 2023 were $399.4 million, up
21%, reflecting operational growth measured at constant exchange
rates (CER)1 of 20% and favorable currency impact of $2.7 million
or 1%. Fourth quarter total revenues were $115.1 million, up 31%,
or 27% at CER.
(in thousands) |
Three Months Ended December 31, |
|
Year over Year %Growth |
|
Twelve Months EndedDecember
31, |
|
Year over Year %Growth |
|
2023 |
|
2022 |
|
Reported |
|
at CER1 |
|
2023 |
|
2022 |
|
Reported |
|
at CER1 |
Galafold® |
106,600 |
|
87,989 |
|
21% |
|
18% |
|
387,777 |
|
329,046 |
|
18% |
|
17% |
Pombiliti™+ Opfolda™ |
8,482 |
|
107 |
|
n/a |
|
n/a |
|
11,579 |
|
187 |
|
n/a |
|
n/a |
Net Product Revenues |
$115,082 |
|
$88,096 |
|
31% |
|
27% |
|
$399,356 |
|
$329,233 |
|
21% |
|
20% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Galafold
(migalastat) net product sales for the full-year 2023 were $387.8
million, representing a year-over-year increase of 18%, or
17% at CER. Fourth quarter net product sales were $106.6 million.
At the end of 2023, there were >2,400 people living with Fabry
disease on Galafold following a year of increased demand.
-
Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat)
net product sales for the full-year 2023 were $11.6
million. Fourth quarter net product sales were $8.5
million. The commercial launch of Pombiliti + Opfolda is underway
in the three largest markets with 120 patients on treatment with
commercial product or scheduled to be treated as of early January
and continued strong patient demand.
- Eleven
posters and an oral presentation highlighting Amicus’ development
programs in Fabry disease and Pompe disease presented at the 20th
Annual WORLDSymposium™.
Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) honored
with the 2024 New Treatment Award, which recognizes important
achievements in advancing new treatments approved for lysosomal
diseases.
- On a GAAP basis, net loss in the fourth quarter of 2023
was $33.8 million. The Company achieved non-GAAP
profitability3 in the fourth
quarter of 2023 of $2.6 million.
Full-Year 2023 Financial Results
- Total revenue in the full-year 2023 was $399.4 million, a
year-over-year increase of 21% from total revenue of $329.2 million
in the full-year 2022. On a constant currency basis, full-year 2023
total revenue growth was 20%. Reported revenue had a favorable
currency impact of approximately $2.7 million, or 1%.
- Total GAAP operating expenses of $439.2 million for the
full-year 2023 decreased by 13% as compared to $502.8 million for
the full-year 2022.
- Total non-GAAP operating expenses of $341.6 million for the
full-year 2023 decreased by 17% as compared to $413.2 million for
the full-year 2022.
- GAAP net loss was $151.6 million, or $0.51 per share, for the
full-year 2023, and was reduced compared to a net loss of $236.6
million, or $0.82 per share, for the full-year 2022.
- Non-GAAP net loss was $38.5 million, or $0.13 per share, for
the full-year 2023, and was reduced compared to a net loss of
$152.5 million, or $0.53 per share, for the full-year 2022.
- Cash, cash equivalents, and marketable securities totaled
$286.2 million at December 31, 2023, compared to $293.6 million at
December 31, 2022.
2024 Financial Guidance
- For the full-year 2024, the Company
anticipates total Galafold revenue growth between 11% and 16% at
CER1 driven by continued underlying demand from both switch and
treatment-naïve patients, geographic expansion, label extensions,
the continued diagnosis of new Fabry patients, and commercial
execution across all major markets, including the U.S., EU, U.K.,
and Japan.
- Non-GAAP operating expense guidance
for the full-year 2024 is $345 million to $365 million, driven by
disciplined expense management offset by continued investment in
Galafold, Pombiliti + Opfolda clinical studies, as well as global
launch activities4.
Amicus is focused on the following key strategic
priorities in 2024:
- Delivering double-digit Galafold
revenue growth (11-16% at CER)
- Executing multiple successful
launches of Pombiliti + Opfolda
- Advancing ongoing studies to
support medical and scientific leadership in Fabry and Pompe
diseases
- Achieving full year non-GAAP
profitability2
1 In order to illustrate underlying performance,
Amicus discusses its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates had remained unchanged from those used in the comparative
period. Full-year 2024 Galafold revenue guidance utilizes actual
exchange rate as of December 31, 2023.2 Based on projections of
Amicus’ non-GAAP Net (Loss) Income under current operating plans,
which includes successful Pombiliti + Opfolda launches and
continued Galafold growth. Amicus defines non-GAAP Net (Loss)
Income as GAAP Net (Loss) Income excluding the impact of
share-based compensation expense, changes in fair value of
contingent consideration, loss on impairment of assets,
depreciation and amortization, acquisition related income
(expense), loss on extinguishment of debt, restructuring charges
and income taxes.3 Full reconciliation of GAAP results to the
Company’s non-GAAP adjusted measures for all reporting periods
appear in the tables to this press release.4 A reconciliation of
the differences between the non-GAAP expectation and the
corresponding GAAP measure is not available without unreasonable
effort due to high variability, complexity, and low visibility as
to the items that would be excluded from the GAAP measure.
Conference Call and
WebcastAmicus Therapeutics will host a conference
call and audio webcast today, February 28, 2024, at 8:30 a.m. ET to
discuss the full-year 2023 financial results and corporate updates.
Participants and investors interested in accessing the call by
phone will need to register using the online registration form.
After registering, all phone participants will receive a dial-in
number along with a personal PIN number to access the event.
A live audio webcast and related presentation
materials can also be accessed via the Investors section of the
Amicus Therapeutics corporate website at ir.amicusrx.com. Web
participants are encouraged to register on the website 15 minutes
prior to the start of the call. An archived webcast and
accompanying slides will be available on the Company's website
shortly after the conclusion of the live event.
About
Galafold Galafold® (migalastat)
123 mg capsules is an oral pharmacological chaperone of
alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry
disease in adults who have amenable galactosidase alpha gene
(GLA) variants. In these patients, Galafold works by
stabilizing the body’s own dysfunctional enzyme so that it can
clear the accumulation of disease substrate. Globally, Amicus
Therapeutics estimates that approximately 35 to 50 percent of
people living with Fabry disease may have
amenable GLA variants, though amenability rates within
this range vary by geography. Galafold is approved in more than 40
countries around the world, including the U.S., EU, U.K., and
Japan.
U.S. INDICATIONS AND USAGEGalafold is indicated
for the treatment of adults with a confirmed diagnosis of Fabry
disease and an amenable galactosidase alpha gene (GLA) variant
based on in vitro assay data.
This indication is approved under accelerated approval based on
reduction in kidney interstitial capillary cell
globotriaosylceramide (KIC GL-3) substrate. Continued approval for
this indication may be contingent upon verification and description
of clinical benefit in confirmatory trials.
U.S. IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONSThe most common adverse
reactions reported with Galafold (≥10%) were headache,
nasopharyngitis, urinary tract infection, nausea and pyrexia.
USE IN SPECIFIC POPULATIONSThere is
insufficient clinical data on Galafold use in pregnant women to
inform a drug-associated risk for major birth defects and
miscarriage. Advise women of the potential risk to a fetus.
It is not known if Galafold is present in human milk. Therefore,
the developmental and health benefits of breastfeeding should be
considered along with the mother’s clinical need for Galafold and
any potential adverse effects on the breastfed child from Galafold
or from the underlying maternal condition.
Galafold is not recommended for use in patients with severe
renal impairment or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been
established in pediatric patients.
To report Suspected Adverse Reactions, contact Amicus
Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
For additional information about Galafold, including the full
U.S. Prescribing Information, please
visit https://www.amicusrx.com/pi/Galafold.pdf.
About Pombiliti +
OpfoldaPombiliti + Opfolda, is a two-component therapy
that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched
rhGAA that facilitates high-affinity uptake through the M6P
receptor while retaining its capacity for processing into the most
active form of the enzyme, and the oral enzyme stabilizer,
miglustat, that’s designed to reduce loss of enzyme activity in the
blood.
U.S. INDICATIONS
AND USAGEPOMBILITI in combination
with OPFOLDA is indicated for the treatment of adult patients with
late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA]
deficiency) weighing ≥40 kg and who are not improving on their
current enzyme replacement therapy (ERT).
SAFETY INFORMATION
HYPERSENSITIVITY REACTIONS INCLUDING
ANAPHYLAXIS: Appropriate medical support measures, including
cardiopulmonary resuscitation equipment, should be readily
available. If a severe hypersensitivity reaction occurs, POMBILITI
should be discontinued immediately and appropriate medical
treatment should be initiated. INFUSION-ASSOCIATED REACTIONS
(IARs): If severe IARs occur, immediately discontinue POMBILITI and
initiate appropriate medical treatment. RISK OF ACUTE
CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients
susceptible to fluid volume overload, or those with acute
underlying respiratory illness or compromised cardiac or
respiratory function, may be at risk of serious exacerbation of
their cardiac or respiratory status during POMBILITI infusion. See
PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI
in combination with Opfolda is contraindicated in pregnancy.
EMBRYO-FETAL TOXICITY: May cause embryo-fetal
harm. Advise females of reproductive potential of the potential
risk to a fetus and to use effective contraception during treatment
and for at least 60 days after the last dose. Adverse
Reactions: Most common adverse reactions ≥ 5% are
headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia.
Please see full PRESCRIBING INFORMATION, including BOXED
WARNING, for POMBILITI (cipaglucosidase alfa-atga) LINK and full
PRESCRIBING INFORMATION for OPFOLDA (miglustat) LINK.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
diseases. With extraordinary patient focus, Amicus Therapeutics is
committed to advancing and expanding a pipeline of cutting-edge,
first- or best-in-class medicines for rare diseases. For more
information please visit the company’s website at www.amicusrx.com,
and follow on X and LinkedIn.
Non-GAAP Financial Measures In
addition to financial information prepared in accordance with U.S.
GAAP, this press release also contains adjusted financial measures
that we believe provide investors and management with supplemental
information relating to operating performance and trends that
facilitate comparisons between periods and with respect to
projected information. These adjusted financial measures are
non-GAAP measures and should be considered in addition to, but not
as a substitute for, the information prepared in accordance with
U.S. GAAP. We use these non-GAAP measures as key performance
measures for the purpose of evaluating operational performance and
cash requirements internally. We typically exclude certain GAAP
items that management does not believe affect our basic operations
and that do not meet the GAAP definition of unusual or
non-recurring items. Other companies may define these measures in
different ways. When we provide our expectation for non-GAAP
operating expenses and profitability on a forward-looking basis, a
reconciliation of the differences between the non-GAAP expectation
and the corresponding GAAP measure generally is not available
without unreasonable effort due to potentially high variability,
complexity and low visibility as to the items that would be
excluded from the GAAP measure in the relevant future period, such
as unusual gains or losses. The variability of the excluded items
may have a significant, and potentially unpredictable, impact on
our future GAAP results.
Forward Looking StatementThis
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
relating to preclinical and clinical development of our product
candidates, the timing and reporting of results from preclinical
studies and clinical trials, the prospects and timing of the
potential regulatory approval of our product candidates,
commercialization plans, manufacturing and supply plans, financing
plans, and the projected revenues and cash position for the
Company. The inclusion of forward-looking statements should not be
regarded as a representation by us that any of our plans will be
achieved. Any or all of the forward-looking statements in this
press release may turn out to be wrong and can be affected by
inaccurate assumptions we might make or by known or unknown risks
and uncertainties. For example, with respect to statements
regarding the goals, progress, timing, and outcomes of discussions
with regulatory authorities and pricing and reimbursement
authorities, are based on current information. Actual results may
differ materially from those set forth in this release due to the
risks and uncertainties inherent in our business, including,
without limitation: the potential that results of clinical or
preclinical studies indicate that the product candidates are unsafe
or ineffective; the potential that it may be difficult to enroll
patients in our clinical trials; the potential that regulatory
authorities may not grant or may delay approval for our product
candidates; the potential that required regulatory inspections may
be delayed or not be successful and delay or prevent product
approval; the potential that we may not be successful in
negotiations with pricing and reimbursement authorities; the
potential that we may not be successful in commercializing Galafold
and/or Pombiliti and Opfolda in Europe, the UK, the US and other
geographies; the potential that preclinical and clinical studies
could be delayed because we identify serious side effects or other
safety issues; the potential that we may not be able to manufacture
or supply sufficient clinical or commercial products; and the
potential that we will need additional funding to complete all of
our studies, the manufacturing, and commercialization of our
products. With respect to statements regarding corporate financial
guidance and financial goals and the expected attainment of such
goals and projections of the Company's revenue, non-GAAP
profitability and cash position, actual results may differ based on
market factors and the Company's ability to execute its operational
and budget plans. In addition, all forward-looking statements are
subject to other risks detailed in our Annual Report on Form 10-K
for the year ended December 31, 2023 to be filed today. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and we undertake no obligation to revise or
update this news release to reflect events or circumstances after
the date hereof.
CONTACT:
Investors: Amicus Therapeutics Andrew
FaughnanVice President, Investor
Relationsafaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Head of
Global Corporate Affairs and Communicationsdmoore@amicusrx.com(609)
662-5079
FOLD-G
TABLE 1
Amicus Therapeutics, Inc.Consolidated Statements of
Operations(in thousands, except share and per share
amounts) |
|
Years Ended
December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2021 |
|
Net product
sales |
$ |
399,356 |
|
|
$ |
329,233 |
|
|
$ |
305,514 |
|
Cost of
goods sold |
|
37,326 |
|
|
|
38,599 |
|
|
|
34,466 |
|
Gross
profit |
|
362,030 |
|
|
|
290,634 |
|
|
|
271,048 |
|
Operating
expenses: |
|
|
|
|
|
Research and development |
|
152,381 |
|
|
|
276,677 |
|
|
|
272,049 |
|
Selling, general, and administrative |
|
275,270 |
|
|
|
213,041 |
|
|
|
192,710 |
|
Changes in fair value of contingent consideration payable |
|
2,583 |
|
|
|
1,078 |
|
|
|
6,514 |
|
Loss on impairment of assets |
|
1,134 |
|
|
|
6,616 |
|
|
|
— |
|
Depreciation and amortization |
|
7,873 |
|
|
|
5,342 |
|
|
|
6,209 |
|
Total
operating expenses |
|
439,241 |
|
|
|
502,754 |
|
|
|
477,482 |
|
Loss from
operations |
|
(77,211 |
) |
|
|
(212,120 |
) |
|
|
(206,434 |
) |
Other
(expense) income: |
|
|
|
|
|
Interest income |
|
7,078 |
|
|
|
3,024 |
|
|
|
509 |
|
Interest expense |
|
(50,149 |
) |
|
|
(37,119 |
) |
|
|
(32,471 |
) |
Loss on extinguishment of debt |
|
(13,933 |
) |
|
|
— |
|
|
|
(257 |
) |
Other (expense) income |
|
(15,886 |
) |
|
|
4,176 |
|
|
|
(2,901 |
) |
Loss before
income tax |
|
(150,101 |
) |
|
|
(242,039 |
) |
|
|
(241,554 |
) |
Income tax
(expense) benefit |
|
(1,483 |
) |
|
|
5,471 |
|
|
|
(8,906 |
) |
Net
loss attributable to common stockholders |
$ |
(151,584 |
) |
|
$ |
(236,568 |
) |
|
$ |
(250,460 |
) |
Net loss
attributable to common stockholders per common share — basic
and diluted |
$ |
(0.51 |
) |
|
$ |
(0.82 |
) |
|
$ |
(0.92 |
) |
Weighted-average common shares outstanding — basic and
diluted |
|
295,164,515 |
|
|
|
289,057,198 |
|
|
|
271,421,986 |
|
TABLE 2
Amicus Therapeutics, Inc.Consolidated Balance
Sheets(in thousands, except share and per share
amounts) |
|
December 31, |
|
|
2023 |
|
|
|
2022 |
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
246,994 |
|
|
$ |
148,813 |
|
Investments in marketable securities |
|
39,206 |
|
|
|
144,782 |
|
Accounts receivable |
|
87,632 |
|
|
|
66,196 |
|
Inventories |
|
59,696 |
|
|
|
23,816 |
|
Prepaid expenses and other current assets |
|
49,533 |
|
|
|
40,209 |
|
Total current assets |
|
483,061 |
|
|
|
423,816 |
|
Operating lease right-of-use assets, net |
|
26,312 |
|
|
|
29,534 |
|
Property and equipment, less accumulated depreciation of $25,429
and $22,281 at December 31, 2023 and 2022, respectively |
|
31,667 |
|
|
|
30,778 |
|
Intangible assets, less accumulated amortization of $2,510 and $0
at December 31, 2023 and December 31, 2022, respectively |
|
20,490 |
|
|
|
23,000 |
|
Goodwill |
|
197,797 |
|
|
|
197,797 |
|
Other non-current assets |
|
18,553 |
|
|
|
19,242 |
|
Total
Assets |
$ |
777,880 |
|
|
$ |
724,167 |
|
Liabilities and
Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
15,120 |
|
|
$ |
15,413 |
|
Accrued expenses and other current liabilities |
|
144,245 |
|
|
|
93,636 |
|
Contingent consideration payable |
|
— |
|
|
|
21,417 |
|
Operating lease liabilities |
|
8,324 |
|
|
|
8,552 |
|
Total current liabilities |
|
167,689 |
|
|
|
139,018 |
|
Long-term debt |
|
387,858 |
|
|
|
391,990 |
|
Operating lease liabilities |
|
48,877 |
|
|
|
51,578 |
|
Other non-current liabilities |
|
13,282 |
|
|
|
18,534 |
|
Total liabilities |
|
617,706 |
|
|
|
601,120 |
|
Commitments and
contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Common stock, $0.01 par value,
500,000,000 shares authorized, 293,594,209 and 281,108,273 shares
issued and outstanding at December 31, 2023 and 2022,
respectively |
|
2,918 |
|
|
|
2,815 |
|
Additional paid-in
capital |
|
2,836,018 |
|
|
|
2,664,744 |
|
Accumulated other
comprehensive gain (loss): |
|
|
|
Foreign currency translation adjustment |
|
5,429 |
|
|
|
(11,989 |
) |
Unrealized loss on available-for-sale securities |
|
(188 |
) |
|
|
(116 |
) |
Warrants |
|
71 |
|
|
|
83 |
|
Accumulated deficit |
|
(2,684,074 |
) |
|
|
(2,532,490 |
) |
Total stockholders'
equity |
|
160,174 |
|
|
|
123,047 |
|
Total Liabilities and
Stockholders' Equity |
$ |
777,880 |
|
|
$ |
724,167 |
|
TABLE 3
Amicus Therapeutics, Inc.Reconciliation of Non-GAAP
Financial Measures(in thousands)(Unaudited) |
|
|
Years Ended December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
2021 |
Total GAAP operating
expenses |
|
$ |
439,241 |
|
$ |
502,754 |
|
$ |
477,482 |
Research and development: |
|
|
|
|
|
|
Share-based compensation |
|
|
21,469 |
|
|
25,089 |
|
|
17,340 |
Selling, general and administrative: |
|
|
|
|
|
|
Share-based compensation |
|
|
64,608 |
|
|
51,423 |
|
|
40,498 |
Loss on impairment of assets |
|
|
1,134 |
|
|
6,616 |
|
|
— |
Changes in fair value of contingent consideration
payable |
|
|
2,583 |
|
|
1,078 |
|
|
6,514 |
Depreciation and amortization |
|
|
7,873 |
|
|
5,342 |
|
|
6,209 |
Total Non-GAAP operating
expense adjustments |
|
|
97,667 |
|
|
89,548 |
|
|
70,561 |
Total Non-GAAP
operating expenses |
|
$ |
341,574 |
|
$ |
413,206 |
|
$ |
406,921 |
TABLE 4
Amicus Therapeutics, Inc.Reconciliation of Non-GAAP
Financial Measures(in thousands, except share and per share
amounts)(Unaudited) |
|
|
Three Months EndedDecember
31, |
|
Years EndedDecember 31, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
GAAP net
loss |
|
$ |
(33,843 |
) |
|
$ |
(55,865 |
) |
|
$ |
(151,584 |
) |
|
$ |
(236,568 |
) |
Share-based compensation |
|
|
18,095 |
|
|
|
18,626 |
|
|
|
86,077 |
|
|
|
76,512 |
|
Loss on impairment of
assets |
|
|
— |
|
|
|
— |
|
|
|
1,134 |
|
|
|
6,616 |
|
Changes in fair value of
contingent consideration payable |
|
|
— |
|
|
|
1,584 |
|
|
|
2,583 |
|
|
|
1,078 |
|
Depreciation and
amortization |
|
|
2,182 |
|
|
|
1,311 |
|
|
|
7,873 |
|
|
|
5,342 |
|
Loss on extinguishment of
debt |
|
|
13,933 |
|
|
|
— |
|
|
|
13,933 |
|
|
|
— |
|
Income tax expense
(benefit) |
|
|
2,183 |
|
|
|
(14,214 |
) |
|
|
1,483 |
|
|
|
(5,471 |
) |
Non-GAAP net income
(loss) |
|
$ |
2,550 |
|
|
$ |
(48,558 |
) |
|
$ |
(38,501 |
) |
|
$ |
(152,491 |
) |
|
|
|
|
|
|
|
|
|
Non-GAAP net income (loss)
attributable to common stockholders per common share — basic and
diluted |
|
$ |
0.01 |
|
|
$ |
(0.17 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.53 |
) |
Weighted-average common shares
outstanding — basic and diluted |
|
|
300,648,503 |
|
|
|
289,602,648 |
|
|
|
295,164,515 |
|
|
|
289,057,198 |
|
Amicus Therapeutics (NASDAQ:FOLD)
過去 株価チャート
から 5 2024 まで 6 2024
Amicus Therapeutics (NASDAQ:FOLD)
過去 株価チャート
から 6 2023 まで 6 2024